ネツピタント
ネツピタント 物理性質
- 融点 :
- 156.2-160.0 °C
- 沸点 :
- 597.4±50.0 °C(Predicted)
- 比重(密度) :
- 1.255
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- クロロホルム（微量）、DMSO（微量）、メタノール（微量）
- 酸解離定数(Pka):
- 7.89±0.38(Predicted)
- 外見 :
- 個体
- 色:
- ホワイトからオフホワイト
- InChIKey:
- WAXQNWCZJDTGBU-UHFFFAOYSA-N
- SMILES:
- C(N(C)C1=C(C2C=CC=CC=2C)C=C(N2CCN(C)CC2)N=C1)(=O)C(C1C=C(C(F)(F)F)C=C(C(F)(F)F)C=1)(C)C
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
Sigma-Aldrich Japan
|
SML2755 |
≥98% (HPLC)
Netupitant ≥98% (HPLC) |
290297-26-6 |
10MG |
￥12100 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
SML2755 |
≥98% (HPLC)
Netupitant ≥98% (HPLC) |
290297-26-6 |
50MG |
￥48500 |
2024-03-01 |
購入 |
ネツピタント 化学特性,用途語,生産方法
効能
制吐薬, NK1受容体拮抗薬
説明
Netupitant, originally developed by Helsinn Healthcare and
later licensed to Eisai, Inc., was approved in the USA in October
2014 for the treatment of chemotherapy-induced nausea and emesis.
Akynzeo ® is a fixed-dose combination of the new drug
netupitant and the previously-approved 5-HT3 antagonist palonosetron.
While palonosetron obtained approval previously for treating
nausea and emesis occurring within the first 24 hours (acute
phase) after chemotherapy, netupitant provides a synergistic
effect with palonosetron, assisting in prevention of nausea
and emesis in later stages following chemotherapy (25–120 h after
chemotherapy treatment). Several clinical trials showed that
this combination of netupitant and palonosetron (Akynzeo ?), in
comparison to treatment with palonosetron treatment alone, led
to an improved percentage of patients in all phases who did not
experience any nausea and emesis after undergoing chemotherapy. Netupitant itself joins the class of selective Neurokinin-
1 (NK1) receptor antagonists which, in addition to their use for treating chemotherapy-induced nausea and emesis,
also play an important role as therapies for depression and
anxiety.
使用
Antiemetic.
定義
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin
3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
ネツピタント 上流と下流の製品情報
原材料
準備製品
ネツピタント 生産企業
Global( 190)Suppliers
290297-26-6(ネツピタント)キーワード:
- 290297-26-6
- 2-[3,5-Bis(trifluoromethyl)phenyl]-N-[6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl]-N-methylisobutyramide
- 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide
- Ro 67-31898/000
- 2-(3,5-bis(trifluoroMethyl)phenyl)-N,2-
diMethyl-N-(6-(4-Methylpiperazin-1-yl)-4-
o-tolylpyridin-3-yl)propanaMide
- BenzeneacetaMide, N,a,a-triMethyl-N-[4-(2-Methylphenyl)-6-(4-Methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoroMethyl)-
- 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-
- Ro 67-31898
- Netupitan
- CID 6451149
- CID6451149
- CID-6451149
- Netupitant(CID-6451149)
- 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-y
- NETUPITANT (RO 67-31898)
- Benzeneacetamide, N,α,α-trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-
- 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-meth...
- NetupitantQ: What is
Netupitant Q: What is the CAS Number of
Netupitant Q: What is the storage condition of
Netupitant Q: What are the applications of
Netupitant
- Netupitant
- ネツピタント
- 2-[3,5-ビス(トリフルオロメチル)フェニル]-N,2-ジメチル-N-[4-(2-メチルフェニル)-6-(4-メチルピペラジン-1-イル)ピリジン-3-イル]プロパンアミド
- N-メチル-N-[6-(4-メチルピペラジン-1-イル)-4-(2-メチルフェニル)ピリジン-3-イル]-2-[3,5-ビス(トリフルオロメチル)フェニル]-2-メチルプロパンアミド
- N-メチル-N-[4-(2-メチルフェニル)-6-(4-メチルピペラジノ)-3-ピリジニル]-2-メチル-2-[3,5-ビス(トリフルオロメチル)フェニル]プロパンアミド
- アキンゼオ